Back to Search Start Over

Minimal PK/PD model for simultaneous description of the maximal tolerated dose and metronomic treatment outcomes in mouse tumor models.

Authors :
Terterov IN
Chubenko VA
Knyazev NA
Klimenko VV
Bogdanov AA
Moiseyenko VM
Bogdanov AA
Source :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2021 Nov; Vol. 88 (5), pp. 867-878. Date of Electronic Publication: 2021 Aug 05.
Publication Year :
2021

Abstract

Purpose: Metronomic chemotherapy (MC) is a promising approach where, in contrast to the conventional maximal tolerated dose (MTD) strategy, regular fractionated doses of the drug are used. This approach has proven its efficacy, although drug dosing and scheduling are often chosen empirically. Pharmacokinetic/pharmacodynamic (PK/PD) models provide a way to choose optimal protocols with computational methods. Existing models are usually too complicated and are valid for only a subset of drug schedules. To address this issue, we propose herein a simple model that can describe MC and MTD regimens simultaneously.<br />Methods: The minimal model comprises tumor suppression due to antiangiogenic drug effect together with a cell-kill term, responsible for its cytotoxicity. The model was tested on data obtained on tumor-bearing mice treated with gemcitabine in ether MTD, MC, or combined (MTD + MC) regimens.<br />Results: We conducted a number of tests in which data were divided in various ways into training and validation sets. The model successfully described different trends in the MTD and MC regimens. With parameters obtained by fitting the model to MTD data, the simulations correctly predicted trends in both the MC and combined therapy groups.<br />Conclusion: Our results demonstrate that the proposed model presents a minimal yet efficient tool for modeling outcomes in different treatment regimens in mice. We hope that this model has the potential for use in clinical practice in the development of patient-specific chemotherapy scheduling protocols based on observed treatment response.<br /> (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Details

Language :
English
ISSN :
1432-0843
Volume :
88
Issue :
5
Database :
MEDLINE
Journal :
Cancer chemotherapy and pharmacology
Publication Type :
Academic Journal
Accession number :
34351468
Full Text :
https://doi.org/10.1007/s00280-021-04326-x